The other billion-dollar question in biotech
Beyond all the back-and-forth about Biogen, it’s worth remembering that, any day now, Sage Therapeutics will disclose data that will swing billions of dollars in market value.
Before the end of the year, Sage will announce the results of a Phase 3 trial testing its oral treatment in major depressive disorder. A previous trial suggests the drug has a rapid effect, but one that fades over time.
Those results helped propel Sage to a roughly $8 billion valuation, but they also set up a high-stakes situation. If the drug, SAGE-217, can demonstrate a fast and durable benefit, the company’s share price could rise even further. But analysts warn that if the pill’s effects again wane over time, the company could drop by 30% or more. And if the study fails outright, Sage could be nearly halved.
Before the end of the year, Sage will announce the results of a Phase 3 trial testing its oral treatment in major depressive disorder. A previous trial suggests the drug has a rapid effect, but one that fades over time.
Those results helped propel Sage to a roughly $8 billion valuation, but they also set up a high-stakes situation. If the drug, SAGE-217, can demonstrate a fast and durable benefit, the company’s share price could rise even further. But analysts warn that if the pill’s effects again wane over time, the company could drop by 30% or more. And if the study fails outright, Sage could be nearly halved.
No hay comentarios:
Publicar un comentario